Evaluation of Non Traditional Cardiovascular Risk Factors in Chronic Kidney Disease Patients Starting Dialysis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 400
- 试验地点
- 5
- 主要终点
- Progression of vascular calcifications during a 2 year follow up according to plasma osteoprotegerin level at inclusion
研究概览
简要总结
To evaluate the relationships between bone mineral markers levels at dialysis start and vascular calcification progression during a 2 year follow up
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who has signed the written consent form
- •Patient with chronic renal failure starting dialysis therapy
排除标准
- •Pregnancy
- •Patient with chronic renal failure not yet on dialysis therapy
研究组 & 干预措施
Cardiovascular risk evaluation
Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
干预措施: Plasma osteoprotegerin level (Biological)
Cardiovascular risk evaluation
Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
干预措施: Plasma fibroblast growth factor 23 level (Biological)
Cardiovascular risk evaluation
Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
干预措施: Vascular calcification score (Procedure)
结局指标
主要结局
Progression of vascular calcifications during a 2 year follow up according to plasma osteoprotegerin level at inclusion
时间窗: 2 years after inclusion
osteoprotegerin will be measured in picomol/L; vascular calcifications will be measured at inclusion and after the 2 year follow up
次要结局
- Occurence of cardiovascular events during a 2 year follow up(2 years after inclusion)
- Progression of vascular calcifications during a 2 year follow up according to plasma fibroblast growth factor 23 level at inclusion(2 years after inclusion)